Preview

Rational Pharmacotherapy in Cardiology

Advanced search

EFFECT OF «TREAT-TO-TARGET» ANTIRHEUMATIC THERAPY ON DIASTOLIC DYSFUNCTION OF THE LEFT AND RIGHT VENTRICLES IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS DURING 18 MONTHS OF OBSERVATION

https://doi.org/10.20996/1819-6446-2015-11-4-398-403

Full Text:

Abstract

Aim. To study the effect of «treat-to-target» antirheumatic therapy on diastolic dysfunction of the left (DDLV) and right (DDLV) ventricles in patients with early rheumatoid arthritis (RA) during 18 months of observation.

Material and methods. The study included patients with early RA (n=66; 71% women; age - 56 [46; 61] years) with moderate/high activity (DAS28 5.3 [5.0; 6.2]), seropositive on rheumatoid factor (77%) and/or cyclic citrullinated peptide antibodies (100%), disease modifying anti-rheumatic drugs (DMARD) and glucocorticoids naive. Treatment with methotrexate (MTX) with the escalation of the dose up to 25-30 mg/week subcutaneously was initiated in all the patients. After 3 months in 47 (71%) patients biologics were added to MTX due to its inefficiency. In 18 months remission of RA was achieved in 44% of the patients. 51 (77%) patients had a cardioprotective therapy. The target blood pressure (BP) level was achieved in 38 (58%) patients. Evaluation of traditional cardiovascular risk factors, 24-hour BP monitoring and echocardiography were performed in all patients initially and in 18 months of MTX/MTX + biologics use.

Results. After 18 months DDLV incidence decreased by 7% (from 49% to 42%; p>0.05) and DDRV incidence decreased by 5% (from 24% to 17%; p>0.05). A more significant decrease in DDLV incidence [from 23 (62%) to 18 (49%)] and of DDRV incidence (from 12 (32%) to 6 (16%)] (р=0.05), was found in MTX + biologics group than in MTX only group [DDLV incidence remained unchanged - 7 (28%), and DDRV incidence increased from 3(12%) to 4 (16%); p>0.05]. The normalization of left ventricle (LV) diastolic function in early RA patients depended primarily on the efficacy of antihypertensive treatment, and of right ventricle (RV) diastolic function - on the achievement of target BP level and RA remission. Reduced erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) plasma levels were associated with the improved LV diastolic function [E/A LV and ΔESR (r=-0,3; p<0,04), E/A LV and CRP (r=-0,2; p<0.05), A LV and ESR (r=0.3; p<0.01)] and improved RV diastolic function [ΔA RV and ΔCRP (r=0.4; p<0.003), ΔE RV and ΔCRP (r=0.3; p<0.01), E/A RV and DAS28 (r=-0.5; p<0.001), E/A RV and CRP (r=-0,3; p<0.05)] by the 18th month of the study.

Conclusion. In early RA patients after 18 months the downward trend of DDLV incidence and a significant reduction of DDRV incidence were found, more expressed in patients treated with MTX + biologics. The achievement of RA remission and target BP level is a prerequisite for the normalization of LV and RV diastolic function and slowing the progression of heart failure.

About the Authors

I. G. Kirillova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


D. S. Novikova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


T. V. Popkova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


Yu. N. Gorbunova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


E. I. Markelova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


Yu. O. Korsakova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


O. A. Fomicheva
Institute of Clinical Cardiology named after A.L. Myasnikov, Russian Cardiology Research and Production Complex
Russian Federation
Tretya Cherepkovskaya ul. 15a, Moscow, 121552 Russia


A. V. Volkov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


E. L. Luchikhina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


N. V. Demidova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


K. A. Kasumova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


S. A. Vladimirov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


M. A. Kanonirova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


G. L. Lukina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


A. A. Novikov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


E. N. Aleksandrova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


D. E. Karateev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Kashirskoye shosse, 34A, Moscow, 115522 Russia


References

1. Avina-Zubieta J., Choi H., Sadatsafavi M. et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-7.

2. Maradit-Kremers H., Nicola P.J., Crowson C.S., et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 722-32.

3. Belenkov YN. Patient with CHF in russian outpatient practice: features of patients, diagnosis and treatment (on the EPOHA-O-HSN study). Serdechnaya nedostatochnost' 2009; 5(1): 4-7. Russian (Беленков Ю.Н. Больные с ХСН в российской амбулаторной практике: особенности контингента, диагно-стики и лечения (по материалам исследования ЭПОХА-О-ХСН). Сердечная Недостаточность 2009; 5(1): 4-7).

4. Turiel M, Sitia S, Atzeni F, et al. Cardiac involvement in rheumatoid arthritis. Reumatismo 2009; 61(4): 244-53 (in Italian).

5. Kloch-Badelek M., Kuznetsova T., Sakiewicz W. et al. Prevalence of left ventricular diastolic dysfunction in European populations based on cross-validated diagnostic thresholds. Cardiovascular Ultrasound 2012; 10: 10-9.

6. Abdul Muizz A.M., Mohd Shahrir M.S., Sazliyana S., et al. A cross-sectional study of diastolic dysfunction in rheumatoid arthritis and its association with disease activity. International Journal of Rheumatic Diseases 2011; 14: 18-30.

7. Rexhepaj N., Bajraktari G., Berisha I., et al. Left and right ventricular diastolic functions in patients with rheumatoid arthritis without clinically evident cardiovascular disease. Int J Clin Pract 2006; 60 (6): 683-8.

8. Kirillova IG, Novikova DS, Popkova TV, et al. Diastolic dysfunction of left and right ventricles in patients with early rheumatoid arthritis before DMARD therapy. Ter archive 2015; 37 (5): 16-23. Russian (Ки-риллова И.Г., Новикова Д.С., Попкова Т.В. и др. Диастолическая дисфункция левого и правого желудочков у больных ранним ревматоидным артритом до назначения базисной противоспа-лительной терапии. Терапевтический Архив 2015; 37(5): 16-23).

9. National guidelines for cardiovascular prevention. Kardiovaskulyarnaya Terapia I Profilaktika 2011; 10 (6) suppl 2: 1-26. Russian (Национальные рекомендации по кардиоваскулярной профилакти-ке. Кардиоваскулярная Терапия и Профилактика 2011; 10 (6) Приложение 2: 1-26).

10. Lafitte S. Do we need new echocardiographic prognosticators for the management of heart failure patients? J Am Coll Cardiol 2009; 54: 625-7.

11. Devereux R.B., Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 55: 613-8.

12. Lang R. M., Bierig R. B., Devereux, et al. Recommendations for chamber quantification. Eur J Echocardiography 2006; 7: 79-108.

13. National guidelines for diagnostics and treatment of chronic heart failure (4th rev.). Serdechnaya Nedostatochnost’ 2013; 81(7): 379-472. Russian (Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности (четвертый пересмотр). Сердечная Не-достаточность 2013; 81(7): 379-472).

14. Dinh W, Futh R, Nickl W, et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc Diabetol 2009; 8: 58.

15. Sun M., Chen M., Dawood F. et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 2007; 115: 1398-407.

16. Sriramula S., Haque M., Majid D. et al. Involvement of tumor necrosis factor-alpha in angiotensin IImediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension 2008; 51: 1345-51.

17. Mann D. L., McMurray J.J., Packer M. et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109: 1594-602.

18. Chung E.S., Packer M., Lo K.H. et al. Randomized, double-blind, placebo controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderateto-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-40.

19. Danila M.I., Patkara N.M., Curtisa J.R. et al. Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr Opin Rheum 2008; 20: 327-33.

20. Wolfe F., Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004; 116: 305-11

21. Kobayashi H., Kobayashi Y., Giles J. et al. Tocilizumab Treatment Increases Left Ventricular Ejection Fraction and Decreases Left Ventricular Mass Index in Patients with Rheumatoid Arthritis without Cardiac Symptoms: Assessed Using 3.0 Tesla Cardiac Magnetic Resonance Imaging. J Rheumatol 2014; 41(10): 1916-21.

22. Curtis J.R., Kramer J.M., Martin C. et al. Heart failure among younger rheumatoid arthritis and Crohn’s patients exposed to TNF-alpha antagonists. Rheumatology 2007; 46: 1688-93.

23. Gong K., Zhang Z., Sun X. et al. The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. American heart Joutnal 2005; 151(1): 61-8.

24. Zang Z. et al. Effects of Methotrexate on plasma cytokines and cardiac remodeling and function in postmyocarditis rats. Mediators Inflamm 2009; 2009: 389720.

25. TomášL., LazúrováI., PundováL. et al. Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases. Clin Rheumatol 2013; 32: 61-6.

26. Verdecchia P, Schillaci G, Borgioni C. et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation1998; 97:48-54.


For citation:


Kirillova I.G., Novikova D.S., Popkova T.V., Gorbunova Y.N., Markelova E.I., Korsakova Y.O., Fomicheva O.A., Volkov A.V., Luchikhina E.L., Demidova N.V., Kasumova K.A., Vladimirov S.A., Kanonirova M.A., Lukina G.L., Novikov A.A., Aleksandrova E.N., Karateev D.E., Nasonov E.L. EFFECT OF «TREAT-TO-TARGET» ANTIRHEUMATIC THERAPY ON DIASTOLIC DYSFUNCTION OF THE LEFT AND RIGHT VENTRICLES IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS DURING 18 MONTHS OF OBSERVATION. Rational Pharmacotherapy in Cardiology. 2015;11(4):398-403. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-4-398-403

Views: 383


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)